Journal
CLINICAL INFECTIOUS DISEASES
Volume 71, Issue 10, Pages 2726-2729Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciaa502
Keywords
cirrhosis; direct-acting antiviral agents; eradication; HCV; portal hypertension
Categories
Funding
- Instituto de Salud Carlos III (ISCII) [PI14/01094, PI14-01581, PI14CIII/00011]
- Spanish AIDS Research Network [RD16/0025/0017, RD16/0025/0018]
- ISCIII-Subdireccion General de Evaluacion
- European Funding for Regional Development (FEDER)
- CIBER Theme-Based Research Area for Liver and Digestive Diseases (CIBEREHD) - ISCIII
Ask authors/readers for more resources
This prospective study of 34 patients with HCV cirrhosis (17 HIV positive) with baseline clinically significant portal hypertension (CSPH; HVPG >= 10 mmHg) and SVR after DAA therapy showed that disappearance of CSPH (primary endpoint) is a rare event (6/18 patients; 18%), indicating a persistent risk of clinical progression or death.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
